| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/03/2002 | US20020002203 Administering an effective amount of a compound selected from aryl(and heterocyclic) ureido and aryl(heterocyclic) carboxamido phenoxyisobutyric acids as inhibitor of glycation and advanced glycation endproducts (AGEs) (protein-aging) |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002168 Heterocyclic carboxamides |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002161 5-HT ligands used to treat central nervous system disorders |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002142 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| 01/03/2002 | US20020002141 For inhibiting apoptosis or apoptosis-like cell death |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020001630 Angiogenesis inhibitor |
| 01/03/2002 | DE10030375A1 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL |
| 01/03/2002 | DE10029371A1 Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka Heterocyclic Aminoalkylpyridinderivate as psychotropic drugs |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2709771A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | CA2414409A1 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2414098A1 Human site-1 protease promoter |
| 01/03/2002 | CA2413816A1 Controlled release arginine formulations |
| 01/03/2002 | CA2413768A1 Pharmaceutical compositions for angiogenic therapy |
| 01/03/2002 | CA2413752A1 Substituted phthalides as anti-convulsive drugs |
| 01/03/2002 | CA2413702A1 Carvedilol |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2413201A1 Treatment for cardiovascular disease |
| 01/03/2002 | CA2412640A1 Iminopyrimidine nmda nr2b receptor antagonists |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412535A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412211A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/02/2002 | EP1167526A1 IgE-dependent histamine-releasing factor(HRF)receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof |
| 01/02/2002 | EP1167389A1 Antibodies against the protein SEMP1, methods for their production and uses thereof |
| 01/02/2002 | EP1167386A1 Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 01/02/2002 | EP1167369A1 Novel thiazolobenzimidazole derivatives |
| 01/02/2002 | EP1167367A1 Thienopyrimidine compounds and salts thereof and process for the preparation of the same |
| 01/02/2002 | EP1167360A1 Human chymase inhibitors |
| 01/02/2002 | EP1167357A1 Alpha-substituted carboxylic acid derivatives |
| 01/02/2002 | EP1167342A1 Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 01/02/2002 | EP1167341A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 01/02/2002 | EP1166789A2 Arsenolite containing angiogenesis inhibitor |
| 01/02/2002 | EP1166786A1 Medicinal compositions |
| 01/02/2002 | EP1166785A1 Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation |
| 01/02/2002 | EP1166784A1 Inhibitors for vascular reconstriction after angioplasty |
| 01/02/2002 | EP1166652A1 Utilization of material containing docosapentaenoic acid |
| 01/02/2002 | EP1166102A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165790A1 Protease activated receptor 2 variants |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165601A2 Prodrugs of thrombin inhibitors |
| 01/02/2002 | EP1165591A1 47 human secreted proteins |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165559A1 1,4-diazabicyclo 3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics |
| 01/02/2002 | EP1165554A1 New endothelin converting enzyme inhibitors, their production and their use |
| 01/02/2002 | EP1165548A1 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165543A1 PROCESS FOR PREPARING S-(R*,S*)] -$g(b) - 1- 1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES |
| 01/02/2002 | EP1165542A1 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
| 01/02/2002 | EP1165534A2 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165521A1 FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 01/02/2002 | EP1165518A2 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165513A1 Indolinone compounds as kinase inhibitors |
| 01/02/2002 | EP1165510A1 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165502A1 Diaryl derivatives and their use as medicaments |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165472A1 Methods for the preparation of biphenyl isoxazole sulfonamides |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165136A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
| 01/02/2002 | EP1165135A1 Method of affecting cholesterol catabolism using nucear bile acid receptor |
| 01/02/2002 | EP1165121A2 SUPAR STIMULATING ACTIVITY OF tcuPA-MEDIATED FIBRINOLYSIS AND DIFFERENT USES THEREOF |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165092A1 Cyclopentanone derivatives and their use |
| 01/02/2002 | EP1165089A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies |
| 01/02/2002 | EP1165088A1 Use of vasopeptidase inhibitors to treat angina pectoris |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165084A1 Inhibitors of prenyl-protein transferases |
| 01/02/2002 | EP1165082A1 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165064A2 Novel inhibitors of formation of advanced glycation endproducts (age's) |